Immunotherapy for hepatocellular carcinoma: Current status and future perspectives

doi:10.3748/wjg.v29.i6.1054

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10559)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

374

WORD

110

HTML

8265

Figures (1-4)

351

Tables (1-3)

411

Sum=9511

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

228

Download

593

Sum=821

Feb 14, 2023 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (53)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Feb 14, 2023; 29(6): 1054-1075
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.1054

Full Size Figure Download Figure

Figure 3 Immune checkpoint inhibitors in hepatocellular carcinoma. CTLA4: Cytotoxic T lymphocyte antigen 4; PD-1: Programmed cell death-1; PD-L1: Programmed cell death-ligand 1.

Citation: Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2023; 29(6): 1054-1075
URL: https://www.wjgnet.com/1007-9327/full/v29/i6/1054.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i6.1054